Zealand Pharma reports positive phase III results against congenital hyperinsulinism

In a phase III study of dasiglucagon, biotech firm Zealand Pharma has met its endpoint, reducing the need for children under 12 months with the rare disorder to undergo intensive hospital treatment by 55%.

Photo: Zealand Pharma / PR

On Thursday, Zealand Pharma has announced positive topline results from a phase III trial of dasiglucagon, a treatment for congenital hyperinsulinism (CHI), the firm reports in a press release.

CHI is a very rare pediatric disease that affects the body’s insulin levels. Due to a genetic defect, children with CHI produce more insulin than needed, resulting in frequent episodes of low blood sugar, known as hypoglycemia.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs